重症肌无力的免疫调节剂和免疫抑制剂：一项网状荟萃分析。
Immunomodulators and immunosuppressants for myasthenia gravis: a network meta-analysis.
作者信息
Varela Lucia B, Meza Nicolás, Escobar Liquitay Camila Micaela, Díaz Menai Samanta, Franco Juan, Garegnani Luis
机构信息
Universidad Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.
Neurology Department, Italian Hospital of Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina.
出版信息
Cochrane Database Syst Rev. 2025 Jun 4;6(6):CD016208. doi: 10.1002/14651858.CD016208.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: Primary To assess the comparative benefits and harms of immunomodulators and immunosuppressants for people with generalised myasthenia gravis through a network meta-analysis. Secondary To estimate the relative ranking of immunomodulators and immunosuppressants according to their effects.
摘要
这是一项Cochrane系统评价（干预措施）的方案。目标如下：主要目标 通过网状Meta分析评估免疫调节剂和免疫抑制剂对全身型重症肌无力患者的相对获益与危害。次要目标 根据免疫调节剂和免疫抑制剂的效果估计其相对排名。
相似文献
1
Immunomodulators and immunosuppressants for myasthenia gravis: a network meta-analysis.
Cochrane Database Syst Rev. 2025 Jun 4;6(6):CD016208. doi: 10.1002/14651858.CD016208.
2
Interventions for central serous chorioretinopathy: a network meta-analysis.
Cochrane Database Syst Rev. 2025 Jun 16;6(6):CD011841. doi: 10.1002/14651858.CD011841.pub3.
3
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.
Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x.
4
Effectiveness of different pharmacological or non-pharmacological interventions on preventing coughing during extubation: a protocol for a systematic review and network meta-analysis.
BMJ Open. 2024 Nov 20;14(11):e081592. doi: 10.1136/bmjopen-2023-081592.
5
Effects of different exercise interventions on chemotherapy-related cognitive impairment in patients with breast cancer: a study protocol for systematic review and network meta-analysis.
BMJ Open. 2024 Apr 17;14(4):e078934. doi: 10.1136/bmjopen-2023-078934.
6
Efficacy and safety of pharmacological treatments in inclusion body myositis: a systematic review.
RMD Open. 2025 Jan 22;11(1):e005176. doi: 10.1136/rmdopen-2024-005176.
7
Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis.
Health Technol Assess. 2024 Dec 11:1-71. doi: 10.3310/PCGV5709.
8
Comparative effectiveness of glucagon-like peptide-1 receptor agonists on body composition and anthropometric indices: A protocol for a systematic review and network meta-analysis of randomized controlled trials.
PLoS One. 2024 Feb 26;19(2):e0297488. doi: 10.1371/journal.pone.0297488. eCollection 2024.
9
The effects of major dietary patterns on patients with type 2 diabetes: Protocol for a systematic review and network meta-analysis.
PLoS One. 2024 Jun 28;19(6):e0306336. doi: 10.1371/journal.pone.0306336. eCollection 2024.
10
Endoscopic treatment of obesity: A protocol of updated systematic review with network meta-analysis of randomized controlled trials.
PLoS One. 2024 Sep 6;19(9):e0308410. doi: 10.1371/journal.pone.0308410. eCollection 2024.
本文引用的文献
1
Myasthenia gravis in 2025: five new things and four hopes for the future.
J Neurol. 2025 Feb 22;272(3):226. doi: 10.1007/s00415-025-12922-7.
2
New treatment strategies in Myasthenia gravis.
Rev Neurol (Paris). 2024 Nov;180(9):971-981. doi: 10.1016/j.neurol.2024.09.006. Epub 2024 Oct 7.
3
Efficacy and safety of tocilizumab in patients with refractory generalized myasthenia gravis.
CNS Neurosci Ther. 2024 Jun;30(6):e14793. doi: 10.1111/cns.14793.
4
FcRn Inhibitor Therapies in Neurologic Diseases.
CNS Drugs. 2024 Jun;38(6):425-441. doi: 10.1007/s40263-024-01090-3. Epub 2024 May 9.
5
Recommendations for the management of myasthenia gravis in Belgium.
Acta Neurol Belg. 2024 Aug;124(4):1371-1383. doi: 10.1007/s13760-024-02552-7. Epub 2024 Apr 22.
6
Promising therapies for the treatment of myasthenia gravis.
Expert Opin Pharmacother. 2024 Mar;25(4):395-408. doi: 10.1080/14656566.2024.2332610. Epub 2024 Mar 25.
7
Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial.
JAMA Neurol. 2024 Mar 4;81(4):336-45. doi: 10.1001/jamaneurol.2024.0044.
8
The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis.
CNS Drugs. 2024 Feb;38(2):93-104. doi: 10.1007/s40263-024-01062-7. Epub 2024 Feb 1.
9
[The Japanese Clinical Guidelines 2022 for Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: An Overview].
Brain Nerve. 2024 Jan;76(1):7-12. doi: 10.11477/mf.1416202551.
10
Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study.
Neurology. 2024 Jan 23;102(2):e207937. doi: 10.1212/WNL.0000000000207937. Epub 2023 Dec 21.
Zotero 插件